Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response

Molecular Pharmacology

Volumn 73, Issue 1, 2008, Pages 243-251

  Lin, Z Ping ^a   Zhu, Yong Lian ^a   Johnson, Dennis R ^a   Rice, Kevin P ^c   Nottoli, Timothy ^a   Hains, Bryan C ^b   McGrath, James ^a   Waxman, Stephen G ^b   Sartorelli, Alan C ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Health Services and Department of Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; FORSKOLIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; PROSTAGLANDIN E2; VINBLASTINE;

ANIMAL CELL; ARTICLE; BLOOD LEVEL; CELL IMMORTALIZATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MALE; METABOLITE; MOUSE; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN THRESHOLD; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; CYCLIC AMP; DINOPROSTONE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PAIN; SIGNAL TRANSDUCTION;

EID: 37349001082     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.039594     Document Type: Article

References (40)

1. Adachi M, Reid G, and Schuetz JD (2002) Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev 54:1333-1342.
2. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, Gallo JM, et al. (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67:262-268.
3. Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J, and Zelcer N (2004) The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 62:1-7.
4. Burian M, and Geisslinger G (2005) COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 107:139-154.
5. Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
6. Chasin M, and Harris DN (1976) Inhibitory and activators of cyclic nucleotide phosphodiesterase. Adv Cyclic Nucleotide Res 7:225-264.
7. Chen ZS, Guo Y, Belinsky MG, Kotova E, and Kruh GD (2005) Transport of bile acids, sulfated steroids, estradiol 17-β-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol 67:545-557.
8. Chen ZS, Lee K, and Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276:33747-33754.
9. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150.
10. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, and Hidaka H (1990) Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMPdependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265:5267-5272.
11. de Waart DR, Paulusma CC, Kunne C, and Oude Elferink RP (2006) Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int 26:362-368.
12. Deeley RG, Westlake C, and Cole SP (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899.
13. Dionne RA, Khan AA and Gordon SM (2001) Analgesia and COX-2 inhibition. Clin Exp Rheumatol 19 (6 Suppl 25):S63-S70.
14. Dirig DM, Salami A, Rathbun ML, Ozaki GT, and Yaksh TL (1997) Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods 76:183-191.
15. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462.
16. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320:229-235.
17. Fitzgerald EM, Okuse K, Wood JN, Dolphin AC and Moss SJ (1999) cAMP-dependent phosphorylation of the tetrodotoxin-resistant voltage-dependent sodium channel SNS. J Physiol 516:433-446.
18. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, and Kruh GD (2003) MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′- dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509-29514.
19. Jedlitschky G, Burchell B, and Keppler D (2000) The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275:30069-30074.
20. Kruh GD, and Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552.
21. Lee K, Klein-Szanto AJ, and Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92:1934-1940.
22. Lin ZP, Belcourt MF, Carbone R, Eaton JS, Penketh PG, Shadel GS, Cory JG, and Sartorelli AC (2007) Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 73:760-772.
23. Lin ZP, Johnson DR, Finch RA, Belinsky MG, Kruh GD, and Sartorelli AC (2002) Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts. Mol Cancer Ther 1:1105-1114.
24. Maher JM, Cheng X, Slitt AL, Dieter MZ, and Klaassen CD (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 33:956-962.
25. Mayr B, and Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2:599-609.
26. Meade EA, Smith WL, and DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614.
27. Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, and McConkey DJ (2005) Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 4:1263-1269.
28. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, and Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 100:9244-9249.
29. Rius M, Thon WF, Keppler D, and Nies AT (2005) Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract. J Urol 174:2409-2414.
30. Sauna ZE, Nandigama K, and Ambudkar SV (2004) Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J Biol Chem 279:48855-48864.
31. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051.
32. Schuster VL (2002) Prostaglandin transport. Prostaglandins Other Lipid Mediat 68-69:633-647.
33. Seamon KB, Padgett W, and Daly JW (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A 78:3363-3367.
34. Shimizu H, Taniguchi H, Hippo Y, Hayashizaki Y, Aburatani H, and Ishikawa T (2003) Characterization of the mouse Abcc12 gene and its transcript encoding an ATP-binding cassette transporter, an orthologue of human ABCC12. Gene 310:17-28.
35. Smith WL, DeWitt DL, and Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182.
36. Taiwo YO, Bjerknes LK, Goetzl EJ, and Levine JD (1989) Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 32:577-580.
37. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
38. Wardlaw SA, Zhang N, and Belinsky SA (2002) Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein. Mol Pharmacol 62:326-333.
39. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, and Borst P (2003) Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 278:17664-17671.
40. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, et al. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97:7476-7481.